Divine Aleru, Microbiome Signatures Research Coordinator

Secnidazole demonstrates dual efficacy in treating bacterial vaginosis by targeting pathogenic anaerobes while preserving beneficial Lactobacillus, validating both its role as a microbiome-based therapeutic intervention (BTI) and the accuracy of V’s microbial signature in guiding effective treatment.

This study confirms secnidazole’s efficacy and safety as a one-dose treatment for V, improving outcomes while supporting microbiome restoration.

Clindamycin is effective in treating bacterial vaginosis by reducing Gardnerella vaginalis and promoting Lactobacillus growth, but recurrence rates highlight the need for adjunct therapies targeting biofilms.

Metronidazole addresses microbial imbalances in bacterial vaginosis by reducing Gardnerella vaginalis and promoting Lactobacillus growth, but biofilm-related resistance may contribute to high recurrence rates. Adjunct therapies are needed for long-term success.

Boric acid restores microbial balance in the vagina by increasing Lactobacillus and reducing harmful species, making it an effective treatment for recurrent V and VC.

This study explores the impact of prebiotic maltose gel on the vaginal microbiota of rhesus macaques, showing its potential to shift microbial balance from V-related bacteria to Lactobacillus dominance, presenting an alternative to antibiotic treatments for bacterial vaginosis.

Boric acid offers promising results for treating resistant vulvovaginal candidiasis, bacterial vaginosis, and trichomoniasis. It shows comparable efficacy to oral itraconazole, with fewer adverse events.

This study assesses the impact of metronidazole on the vaginal microbiota, revealing that high G. vaginalis and pathobionts correlate with treatment failure, suggesting a need for biofilm-disrupting therapies in some V patients.

This review discusses bacterial vaginosis, biofilm formation, and emerging therapies targeting biofilms for more effective V treatments.

This review explores the antimicrobial potential of essential oils (Os) in combating microbial biofilms, highlighting their effectiveness against pathogens like S. aureus and C. albicans. Os can serve as an alternative or adjunct to conventional antibiotics, particularly in medical device infections.